SG81890A1 - Compounds for treating a condition or disease in a human related to supranormal intracellular enzyme activity - Google Patents
Compounds for treating a condition or disease in a human related to supranormal intracellular enzyme activityInfo
- Publication number
- SG81890A1 SG81890A1 SG9607743A SG1996007743A SG81890A1 SG 81890 A1 SG81890 A1 SG 81890A1 SG 9607743 A SG9607743 A SG 9607743A SG 1996007743 A SG1996007743 A SG 1996007743A SG 81890 A1 SG81890 A1 SG 81890A1
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- condition
- intracellular enzyme
- enzyme activity
- treating
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 5
- 230000003834 intracellular effect Effects 0.000 title abstract 5
- 108090000790 Enzymes Proteins 0.000 title abstract 4
- 102000004190 Enzymes Human genes 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000008777 Glycerylphosphorylcholine Substances 0.000 abstract 2
- 229960004956 glycerylphosphorylcholine Drugs 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 abstract 1
- 108090000371 Esterases Proteins 0.000 abstract 1
- 108010064785 Phospholipases Proteins 0.000 abstract 1
- 102000015439 Phospholipases Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 238000010504 bond cleavage reaction Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL10524493A IL105244A (en) | 1993-03-31 | 1993-03-31 | Prodrugs with enhanced penetration into cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG81890A1 true SG81890A1 (en) | 2001-07-24 |
Family
ID=11064681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG9607743A SG81890A1 (en) | 1993-03-31 | 1994-03-30 | Compounds for treating a condition or disease in a human related to supranormal intracellular enzyme activity |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5985854A (de) |
| EP (1) | EP0691852B1 (de) |
| JP (1) | JP3900533B2 (de) |
| KR (1) | KR100400075B1 (de) |
| AT (1) | ATE259661T1 (de) |
| AU (1) | AU682029B2 (de) |
| CA (1) | CA2159610C (de) |
| DE (1) | DE69433560T2 (de) |
| HU (1) | HU221678B1 (de) |
| IL (1) | IL105244A (de) |
| NZ (1) | NZ263208A (de) |
| SG (1) | SG81890A1 (de) |
| WO (1) | WO1994022483A2 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714167A (en) * | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| US7135584B2 (en) * | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
| AU3216695A (en) * | 1994-08-29 | 1996-03-22 | University Of North Carolina At Chapel Hill, The | Lipid analogs for treating viral infections |
| US6313106B1 (en) | 1995-06-07 | 2001-11-06 | D-Pharm Ltd. | Phospholipid derivatives of valproic acid and mixtures thereof |
| CA2227013A1 (en) * | 1995-07-14 | 1997-02-06 | Glycotech Corp. | Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor |
| US6350780B1 (en) * | 1995-07-28 | 2002-02-26 | Allergan Sales, Inc. | Methods and compositions for drug delivery |
| US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| JP2001512425A (ja) | 1997-02-11 | 2001-08-21 | セラマーク・リミテッド | 薬物ターゲティング |
| AU751876B2 (en) * | 1997-03-19 | 2002-08-29 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
| JP2001512830A (ja) | 1997-08-08 | 2001-08-28 | ニューバイオティックス インコーポレイテッド | 生物療法耐性および化学療法耐性を克服するための方法および組成物 |
| EP1240922B1 (de) * | 1997-08-08 | 2008-11-12 | Celmed Oncology (USA), Inc. | Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden |
| CA2317505C (en) * | 1998-01-23 | 2011-01-04 | Newbiotics, Inc. | Enzyme catalyzed therapeutic agents |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| US7235583B1 (en) | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
| CA2378187C (en) * | 1999-07-22 | 2011-09-13 | Newbiotics, Inc. | Methods for treating therapy-resistant tumors |
| US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
| IL131887A0 (en) | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| US6670341B1 (en) | 1999-10-28 | 2003-12-30 | Wake Forest University Health Sciences | Compositions and methods for double-targeting virus infections and targeting cancer cells |
| US7026469B2 (en) * | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
| CZ20022507A3 (cs) * | 2000-01-20 | 2003-01-15 | Omegatech, Inc. | Způsob chování králíků |
| US20020115642A1 (en) * | 2000-05-02 | 2002-08-22 | Chan Ming Fai | Beta-lactam antibiotics |
| US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
| CA2441350A1 (en) | 2001-01-19 | 2002-07-25 | Newbiotics, Inc. | Methods to treat autoimmune and inflammatory conditions |
| AU2002303164A1 (en) | 2001-03-23 | 2002-10-08 | Protarga, Inc. | Fatty amine drug conjugates |
| ES2387562T3 (es) | 2001-03-23 | 2012-09-26 | Luitpold Pharmaceuticals, Inc. | Conjugados alcohol graso-medicamento |
| US7410956B2 (en) | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
| US20050187191A1 (en) * | 2004-02-20 | 2005-08-25 | Kucera Louis S. | Methods and compositions for the treatment of respiratory syncytial virus |
| USD692565S1 (en) * | 2010-06-03 | 2013-10-29 | Smith & Nephew, Inc. | Organ protection layer |
| CA140188S (en) | 2010-10-15 | 2011-11-07 | Smith & Nephew | Medical dressing |
| CA140189S (en) | 2010-10-15 | 2011-11-07 | Smith & Nephew | Medical dressing |
| EP2948139B1 (de) * | 2013-01-28 | 2019-06-12 | Lopez, Hector, L. | Verfahren zur verbesserung der verträglichkeit, pharmakodynamik und wirksamkeit von b-alanin und verwendung davon |
| CN108659038B (zh) * | 2017-03-31 | 2022-01-11 | 江苏恩华药业股份有限公司 | 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法 |
| CN110407867A (zh) * | 2018-04-28 | 2019-11-05 | 江苏恩华药业股份有限公司 | 丙戊酸磷脂衍生物的新晶型及其制备方法 |
| CN111334369B (zh) * | 2020-03-11 | 2022-10-21 | 陕西科技大学 | 一种酶法制备卵磷脂型pufa的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR244F (de) * | 1900-01-01 | |||
| EP0032516B1 (de) * | 1980-01-16 | 1984-05-02 | Lacer, S.A. | 2-Halo-pyridine, ihre Herstellung und pharmazeutische Zusammensetzungen |
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| IT1201151B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono |
| IT1201149B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche |
| WO1989005358A1 (en) * | 1987-11-30 | 1989-06-15 | University Of Iowa Research Foundation | Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
| DE3801587A1 (de) * | 1988-01-21 | 1989-08-03 | Hoechst Ag | Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung |
| WO1990010448A2 (en) * | 1989-03-07 | 1990-09-20 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| JPH03133987A (ja) * | 1989-10-18 | 1991-06-07 | Kowa Yakuhin Kogyo Kk | ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法 |
| JPH03275625A (ja) * | 1990-03-23 | 1991-12-06 | Nippon Oil & Fats Co Ltd | 制癌剤およびその製造法 |
| AU7872491A (en) * | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| CH679856A5 (de) * | 1990-07-04 | 1992-04-30 | Lonza Ag | |
| US5149794A (en) * | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| WO1992017185A1 (en) * | 1991-03-29 | 1992-10-15 | University Of Florida | Targeted drug delivery via mixed phosphate derivatives |
| EP0594677A4 (en) * | 1991-07-12 | 1997-09-17 | Vical Inc | Antiviral liponucleosides: treatment of hepatitis b |
| US6015834A (en) * | 1992-10-20 | 2000-01-18 | Toronto Neuroprotection Group | In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer |
-
1993
- 1993-03-31 IL IL10524493A patent/IL105244A/xx not_active IP Right Cessation
-
1994
- 1994-03-30 SG SG9607743A patent/SG81890A1/en unknown
- 1994-03-30 WO PCT/GB1994/000669 patent/WO1994022483A2/en active IP Right Grant
- 1994-03-30 EP EP94911239A patent/EP0691852B1/de not_active Expired - Lifetime
- 1994-03-30 US US08/481,243 patent/US5985854A/en not_active Expired - Lifetime
- 1994-03-30 AU AU63808/94A patent/AU682029B2/en not_active Ceased
- 1994-03-30 CA CA002159610A patent/CA2159610C/en not_active Expired - Fee Related
- 1994-03-30 KR KR1019950704313A patent/KR100400075B1/ko not_active IP Right Cessation
- 1994-03-30 JP JP52182794A patent/JP3900533B2/ja not_active Expired - Fee Related
- 1994-03-30 AT AT94911239T patent/ATE259661T1/de not_active IP Right Cessation
- 1994-03-30 NZ NZ263208A patent/NZ263208A/en not_active IP Right Cessation
- 1994-03-30 HU HU9502866A patent/HU221678B1/hu not_active IP Right Cessation
- 1994-03-30 DE DE69433560T patent/DE69433560T2/de not_active Expired - Lifetime
-
1999
- 1999-03-16 US US09/270,392 patent/US6136796A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE259661T1 (de) | 2004-03-15 |
| US5985854A (en) | 1999-11-16 |
| DE69433560T2 (de) | 2004-12-16 |
| AU682029B2 (en) | 1997-09-18 |
| US6136796A (en) | 2000-10-24 |
| WO1994022483A2 (en) | 1994-10-13 |
| AU6380894A (en) | 1994-10-24 |
| JPH08508295A (ja) | 1996-09-03 |
| HU9502866D0 (en) | 1995-11-28 |
| CA2159610C (en) | 2008-05-20 |
| WO1994022483A3 (en) | 1994-12-22 |
| HUT73669A (en) | 1996-09-30 |
| JP3900533B2 (ja) | 2007-04-04 |
| EP0691852A1 (de) | 1996-01-17 |
| EP0691852B1 (de) | 2004-02-18 |
| IL105244A (en) | 2003-07-31 |
| NZ263208A (en) | 1997-06-24 |
| DE69433560D1 (de) | 2004-03-25 |
| CA2159610A1 (en) | 1994-10-01 |
| IL105244A0 (en) | 1993-07-08 |
| KR100400075B1 (ko) | 2004-02-25 |
| HU221678B1 (hu) | 2002-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG81890A1 (en) | Compounds for treating a condition or disease in a human related to supranormal intracellular enzyme activity | |
| EP1127579A3 (de) | Verfahren zur Erhöhen der Bioverfügbarkeit oraler Arzneimittel | |
| RS20090086A (en) | Nucleoside analogs with carobxamidine modified monocyclic base | |
| WO2000028981A3 (en) | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor | |
| HRP20030879A2 (en) | Pharmaceutically active uridine esters | |
| IL139960A0 (en) | Macrocylic analogs and methods of their use and preparation | |
| CA2301017A1 (en) | Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds | |
| NO180490C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 2,6-dialkyl-4-silylfenoler | |
| TR199801195T2 (xx) | Tedavide yararl� kinolin ve kinozilin bile�ikleri. | |
| CA2294812A1 (fr) | Composition pharmaceutique solide contenant des derives de benzofuranne | |
| CA2040865A1 (en) | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | |
| EP1302207A3 (de) | Verfahren zur Herstellung eines bluddrucksenkenden Mittel enthaltenden ein Dipeptid als wirksames Bestandteil | |
| WO1999012951A8 (en) | Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases | |
| AU5805096A (en) | Transdermal therapeutic system (TTS) for the administration of testosterone | |
| WO1999056734A3 (de) | Transdermales therapeutisches system zur anwendung von candesartan | |
| TW330933B (en) | Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes | |
| AU3581695A (en) | Method and means for prevention and treatment of secondary cataract | |
| AU1875395A (en) | 4-amino derivatives of 5-substituted mycophenolic acid | |
| AU637861B2 (en) | Improved system for the transdermal application of pharmacologically active compounds at controlled ph | |
| HUP0004616A2 (hu) | Tetrahidrofurán-származék hidroxi-észtere mint gombaellenes szer prodrogja | |
| DE69711429D1 (en) | Nitromethylthiobenzolderivate als aldose-reductase-inhibitoren | |
| UA66809C2 (uk) | Спосіб лікування гіперглікемії похідною тіазолідиндіону | |
| DE69705772T2 (de) | Adamantyl substituierte Oxindole als pharmazeutische Wirkstoffe | |
| DE60040856D1 (de) | Lactalbumin zur kurativen Behandlung von Magengeschwüren |